Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Share:
Related MRK
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Fast Money Halftime Report Final Trade From January 27
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Merck & Co. closed on Thursday at $48.73.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2015Deutsche BankMaintainsHold
Jan 2015BarclaysUpgradesUnderweightEqualweight
Jan 2015JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters